Quantcast

Industry news that matters to you.  Learn more

Archives for June 2014

IU, Paradigm Team Up to Test Genomic Sequencing for Women with Aggressive Form of Breast Cancer

Indiana University cancer researchers are testing whether therapy incorporating advanced genomic technology will provide better outcomes than current treatments for those with an aggressive form of breast cancer.

Enterome and Mayo Clinic Enter Collaboration to Develop and Commercialize Microbiome-based Diagnostic Tools for Nutritional Interventions

ENTEROME Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, is pleased to announce it has entered into an agreement with Mayo Clinic. The collaboration is focused on the discovery and validation of gut microbiome-based diagnostic tests for predicting response to medical nutritional intervention in obese or overweight patients.

Groundbreaking Collaborative Clinical Trial Launched

A unique public-private collaboration among the National Cancer Institute (NCI), part of the National Institutes of Health, SWOG Cancer Research, Friends of Cancer Research (Friends), the Foundation for the National Institutes of Health (FNIH), five pharmaceutical companies (Amgen, Genentech, Pfizer, AstraZeneca, and AstraZeneca’s global biologics R&D arm, MedImmune), and Foundation Medicine today announced the initiation of the Lung Cancer Master Protocol (Lung-MAP) trial. 

KalGene Pharmaceuticals, Sunnybrook Research Institute, Ontario Cancer Biomarker Network and CIMTEC Announce Multi-year Collaboration to Tackle Aggressive Cancers

KalGene Pharmaceuticals, Inc. (KalGene) is expediting development of a prognostic marker and companion therapeutic that specifically targets aggressive cancers. 

SomaLogic Announces First Early-access Site for SOMAscan Assay

SomaLogic, Inc., recently announced that the Perelman School of Medicine at the University of Pennsylvania is the first biomedical research center that will offer researchers on-site access to the SOMAscan™ assay, the most powerful proteomics platform available today. The assay will be performed at Penn’s Institute for Translational Medicine and Therapeutics (ITMAT), under the leadership of Daniel J. Rader, MD, associate director of ITMAT and chair of the Department of Genetics., and Stephen Master, MD, PhD, assistant professor of Pathology and Laboratory Medicine and director of ITMAT’s Translational Core Laboratory. It is expected that the SOMAscan assay will be fully functional at Penn by midsummer 2014.